Cargando…

CD20 and CD37 antibodies synergize to activate complement by Fc-mediated clustering

CD20 monoclonal antibody therapies have significantly improved the outlook for patients with B-cell malignancies. However, many patients acquire resistance, demonstrating the need for new and improved drugs. We previously demonstrated that the natural process of antibody hexamer formation on targete...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oostindie, Simone C., van der Horst, Hilma J., Lindorfer, Margaret A., Cook, Erika M., Tupitza, Jillian C., Zent, Clive S., Burack, Richard, VanDerMeid, Karl R., Strumane, Kristin, Chamuleau, Martine E. D., Mutis, Tuna, de Jong, Rob N., Schuurman, Janine, Breij, Esther C. W., Beurskens, Frank J., Parren, Paul W. H. I., Taylor, Ronald P.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ferrata Storti Foundation 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6717598/ https://www.ncbi.nlm.nih.gov/pubmed/30792198 http://dx.doi.org/10.3324/haematol.2018.207266

Ejemplares similares

DuoHexaBody-CD37(®), a novel biparatopic CD37 antibody with enhanced Fc-mediated hexamerization as a potential therapy for B-cell malignancies
por: Oostindie, Simone C., et al.
Publicado: (2020)

Potent Preclinical Efficacy of DuoHexaBody-CD37 in B-Cell Malignancies
por: van der Horst, Hilma J., et al.
Publicado: (2020)

Fc-Engineered Antibodies with Enhanced Fc-Effector Function for the Treatment of B-Cell Malignancies
por: van der Horst, Hilma J., et al.
Publicado: (2020)

Epcoritamab induces potent anti-tumor activity against malignant B-cells from patients with DLBCL, FL and MCL, irrespective of prior CD20 monoclonal antibody treatment
por: van der Horst, Hilma J., et al.
Publicado: (2021)

DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing
por: Engelberts, Patrick J., et al.
Publicado: (2020)

A Novel Platform for the Potentiation of Therapeutic Antibodies Based on Antigen-Dependent Formation of IgG Hexamers at the Cell Surface
por: de Jong, Rob N., et al.
Publicado: (2016)

Avidity in antibody effector functions and biotherapeutic drug design
por: Oostindie, Simone C., et al.
Publicado: (2022)

Monoclonal antibodies targeting CD38 in hematological malignancies and beyond
por: van de Donk, Niels W. C. J., et al.
Publicado: (2016)

Preclinical evaluation of CD38 chimeric antigen receptor engineered T cells for the treatment of multiple myeloma
por: Drent, Esther, et al.
Publicado: (2015)

The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies
por: van der Veer, M S, et al.
Publicado: (2011)

Bone Marrow Mesenchymal Stromal Cell-mediated Resistance in Multiple Myeloma Against NK Cells can be Overcome by Introduction of CD38-CAR or TRAIL-variant
por: Holthof, Lisa C., et al.
Publicado: (2021)

A method to extract cytokines and matrix metalloproteinases from Schirmer strips and analyze using Luminex
por: VanDerMeid, Karl R., et al.
Publicado: (2011)

Regulatory T Cell Depletion Using a CRISPR Fc-Optimized CD25 Antibody
por: van Elsas, Marit J., et al.
Publicado: (2022)

The highly selective Bruton tyrosine kinase inhibitor acalabrutinib leaves macrophage phagocytosis intact
por: Pinney, Jonathan J., et al.
Publicado: (2022)

BOL-303242-X, a novel selective glucocorticoid receptor agonist, with full anti-inflammatory properties in human ocular cells
por: Zhang, Jin-Zhong, et al.
Publicado: (2009)

Promoting Fc-Fc interactions between anti-capsular antibodies provides strong immune protection against Streptococcus pneumoniae
por: Aguinagalde Salazar, Leire, et al.
Publicado: (2023)

Preclinical anti-tumour activity of HexaBody-CD38, a next-generation CD38 antibody with superior complement-dependent cytotoxic activity
por: Hiemstra, Ida H., et al.
Publicado: (2023)

Fcγ receptor binding is required for maximal immunostimulation by CD70-Fc
por: Dadas, Osman, et al.
Publicado: (2023)

Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma
por: Overdijk, Marije B, et al.
Publicado: (2015)

Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma
por: Poels, Renée, et al.
Publicado: (2021)

Fc-Optimized Anti-CD25 Depletes Tumor-Infiltrating Regulatory T Cells and Synergizes with PD-1 Blockade to Eradicate Established Tumors
por: Arce Vargas, Frederick, et al.
Publicado: (2017)

P1254: RESPONSE TO DA-EPOCH-R IN PATIENTS WITH HIGH GRADE B CELL LYMPHOMA IS ASSOCIATED WITH A REDUCTION OF PD1 POSITIVE EXHAUSTED CD8 T CELLS
por: de Jonge, V., et al.
Publicado: (2022)

The Antitumor Activities of Anti-CD47 Antibodies Require Fc-FcγR interactions
por: Osorio, Juan C., et al.
Publicado: (2023)

The Human FcγRII (CD32) Family of Leukocyte FcR in Health and Disease
por: Anania, Jessica C., et al.
Publicado: (2019)

Toward targeting B cell cancers with CD4(+) CTLs: identification of a CD19-encoded minor histocompatibility antigen using a novel genome-wide analysis
por: Spaapen, Robbert M., et al.
Publicado: (2008)

Preclinical Rationale for Targeting the PD-1/PD-L1 Axis in Combination with a CD38 Antibody in Multiple Myeloma and Other CD38-Positive Malignancies
por: Verkleij, Christie P. M., et al.
Publicado: (2020)

Antagonizing FcαR1 (CD89) as treatment in IgA-mediated chronic inflammation and autoimmunity
por: van Delft, Myrthe A. M., et al.
Publicado: (2023)

Feasibility of controlling CD38-CAR T cell activity with a Tet-on inducible CAR design
por: Drent, Esther, et al.
Publicado: (2018)

Anti-CD2 receptor and anti-CD2 ligand (CD48) antibodies synergize to prolong allograft survival
Publicado: (1994)

Negative Regulation of FcεRI-mediated Degranulation by CD81
por: Fleming, Tony J., et al.
Publicado: (1997)

CD24Fc: an emerging COVID-19 therapy
por: Eckhardt, Christina M, et al.
Publicado: (2022)

Three-color flow cytometry detection of virus-specific CD4+ and CD8+ T cells in the cat
por: de Groot-Mijnes, Jolanda D.F., et al.
Publicado: (2004)

Human IgG is produced in a pro-form that requires clipping of C-terminal lysines for maximal complement activation
por: van den Bremer, Ewald TJ, et al.
Publicado: (2015)

FcγR-Mediated Trogocytosis 2.0: Revisiting History Gives Rise to a Unifying Hypothesis
por: Lindorfer, Margaret A., et al.
Publicado: (2022)

CD8+CD122+PD-1+ Tregs Synergize With Costimulatory Blockade of CD40/CD154, but Not B7/CD28, to Prolong Murine Allograft Survival
por: Liu, Huazhen, et al.
Publicado: (2019)

Dual Targeting to Overcome Current Challenges in Multiple Myeloma CAR T-Cell Treatment
por: van der Schans, Jort J., et al.
Publicado: (2020)

CD8 and CD4 T Cell Populations in Human Kidneys
por: van der Putten, Carlos, et al.
Publicado: (2021)

Monoclonal antibody (mAb)-based cancer therapy: Is it time to reevaluate dosing strategies?
por: Lindorfer, Margaret A., et al.
Publicado: (2012)

CD38 knockout natural killer cells expressing an affinity optimized CD38 chimeric antigen receptor successfully target acute myeloid leukemia with reduced effector cell fratricide
por: Gurney, Mark, et al.
Publicado: (2020)

Signal transduction by the CD2 antigen in T cells and natural killer cells: requirement for expression of a functional T cell receptor or binding of antibody Fc to the Fc receptor, Fc gamma RIIIA (CD16)
Publicado: (1991)

Cannot write session to /tmp/vufind_sessions/sess_1tu0evdg4r3pbfqv9c0ke1coe6